Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Koki Kawano

Noritaka Kitazawa

Koichi Ito

Teiji Kimura

Toshihiko Kaneko

Mamoru Takaishi

Hiroaki Hagiwara

Takehiko Miyagawa

Kohshi Ueno

Takeo Sasaki

Eriko Doi

Nobuaki Sato

Yoshihiko Norimine

Atsuhiko Kubota

Keiko Takahashi

Atsushi Sasaki

Satoshi Nagato

Manabu Matsunaga

Tadashi Okabe

Yuichi Suzuki

Noboru Yamamoto

Takashi Doko

Makoto Komatsu

Shinji Hatakeyama

Fumihiro Ozaki

Kogyoku Shin

Kohei Sawada

Yu Yoshida

Masataka Ueno

Mutsuko Ono

Takashi Yoshinaga

Kiyoaki Kobayashi

Hiroyuki Suzuki

Hiroe Minami

Takahisa Hanada

Tatsuhiro Onogi

Yoichi Iimura

Daisuke Shinmyo

Daiju Hasegawa

Hiroyuki Amino

Terence Smith

Toshiyuki Uemura

Makoto Ogo

Anthony John Groom

Leanne Rivers

Akiharu Kajiwara

Ikuo Kushida

Yoshio Urawa

Hiroyuki Naka

Tetsuhiro Niidome

Tetsuyuki Teramoto

Tatsuto Fukushima

Disclosed is a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, which is effective as a therapeutic or prophylactic agent for a disease induced by A&#x3b2;, wherein Arrepresents an imidazolyl group which may be substituted with a C1-6 alkyl group, or the like; Arrepresents a phenyl group which may be substituted with a C1-6 alkoxy group, or the like; Xrepresents a double bond, or the like; and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, or the like.

Polycyclic compound

The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): whereinrepresents a single bond or a double bond; Arrepresents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; Rand Reach represent a C1-6 alkyl group, a hydroxyl group, or the like; Zrepresents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing A&#x3b2;40 and A&#x3b2;42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A&#x3b2; such as Alzheimer's disease or Down's syndrome.

Two cyclic cinnamide compound

The present invention relates to a compound represented by formula (I): wherein Rrepresents a C1-3 alkyl group, Rrepresents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.

Bicyclic oxomorpholine derivative

The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A&#x3b2;.

Multi-cyclic cinnamide derivatives

The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof.  In the formula, Q indicates NH, O or S; and R, R, R, Rand Rare the same as or different from each other and each indicates hydrogen atom, a halogen atom, a Calkyl group or a group represented by the formula &#x2014;X-A (wherein X indicates a single bond, an optionally substituted Calkylene group etc.; and A indicates an optionally substituted Caromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).

1,2-dihydropyridine compounds, manufacturing method thereof and use thereof

A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Arrepresents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Arrepresents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, Xrepresents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by A&#x3b2;.

Imidazoyl pyridine compounds and salts thereof

Compounds represented by the following general formula: [wherein X, X, Xand Xeach independently represent a single bond, Calkylene, etc.; Arepresents optionally substituted phenyl, etc.; Arepresents an optionally substituted 5- to 7-membered heterocyclic group containing &#x2014;C(=Q)- (wherein Qrepresents oxygen, sulfur or &#x2550;N&#x2014;R(wherein Rrepresents hydrogen or Calkyl)) and nitrogen, etc.; and Zrepresents piperidin-diyl, etc.],salts thereof and hydrates of the foregoing.

Nitrogen containing heterocyclic compounds and medicines containing the same

The present invention relates to a compound represented by Formula (I): (wherein Arrepresents an imidazolyl group which may be substituted with 1 to 3 substituents; Arrepresents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; Xrepresents (1) &#x2014;C&#x2261;C&#x2014; or (2) a double bond etc. which may be substituted; Rand Rrepresent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.

Cinnamide compound

The present invention provides a most suitable prodrug of a cinnamide compound. The prodrug is represented by Formula (I) wherein Rand Reach denote a C1-6 alkyl group or the like; Xdenotes a methoxy group or a fluorine atom; Y denotes a phosphono group or the like; and A denotes a cyclic lactam derivative.

Prodrug of cinnamide compound

The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Arrepresents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Arrepresents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, Xrepresents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A&#x3b2;.

Multi-cycle cinnamide derivatives

The present invention relates to a process for preparing a compound of formula (6a): wherein Arrepresents an imidazolyl group which may be substituted with 1 to 3 substituents shown below; Arrepresents a pyridinyl group, a pyrimidinyl group or a phenyl group which may be substituted with 1 to 3 substituents; and Rrepresents a group selected from certain substituents.

The present invention relates to a compound represented by Formula (I): (wherein Arrepresents an imidazolyl group which may be substituted with 1 to 3 substituents; Arrepresents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; Xrepresents (1) &#x2014;C&#x2261;C&#x2014; or (2) a double bond etc. which may be substituted; Rand Rrepresent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by A&#x3b2;. According to the present invention, a therapeutic or preventive agents for diseases caused by A&#x3b2; can be provided.

The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R, R, R, and Rare the same or different and each represent a hydrogen atom or a C1-6 alkyl group; Xrepresents a C1-6 alkylene group that may be substituted; Xrepresents a methoxy group or a fluorine atom; Xrepresents an oxygen atom or a methylene group, provided that Xis only an oxygen atom when Xis a methoxy group; and Arrepresents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.

Morpholine type cinnamide compound

Growing community of inventors

Tsukuba, Japan

Koki Kawano